Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Tempus AI's growth in precision oncology drives an 80% revenue boost by 2025. Click here to find out why I rate TEM stock a ...

Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” second-quarter ...

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA portfolio right now.

Former House Speaker Nancy Pelosi said back in 2022 the Senate would soon vote on a bill banning members of Congress from trading individual stocks. Roughly three years later, Pelosi is no ...

Analysts have recently evaluated Tempus AI and provided 12-month price targets. The average target is $67.88, accompanied by a high estimate of $70.00 and a low estimate of $60.00. Observing a 7. ...

Recognizing that breast cancer guidelines, much like those for lung cancer, are constantly evolving, Tempus is working to ...